ArticleBMC gastroenterology2026
Association of red blood cell distribution width to albumin ratio with all-cause and cardiovascular mortality among adults with MASLD.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health burden. Identifying robust prognostic biomarkers is crucial for early risk stratification. The red blood cell distribution width to albumin ratio (RAR) has emerged as a potential biomarker reflecting inflammation and nutritional status. This study aimed to evaluate the association between RAR and both all-cause and cardiovascular mortality among adults with MASLD.
methodsData from the National Health and Nutrition Examination Survey 1999-2018 were analyzed. MASLD was defined using the United States Fatty Liver Index (USFLI ≥ 30), combined with cardiometabolic criteria. Participants were categorized into RAR quartiles. Weighted Cox proportional hazards models, Fine-Gray competing risk models, and restricted cubic splines were employed to the association between RAR and mortality. Stratified and sensitivity analyses were conducted to test robustness.
resultsAmong 6,287 MASLD patients (mean age 51.39 years, 42.69% female), there were 1,161 all-cause deaths and 324 cardiovascular deaths over a median follow-up of 9.2 years. In the fully adjusted Model 3, individuals in the highest RAR quartile had a higher risk of all-cause mortality (hazard ratio [HR] = 2.41, 95% confidence interval [CI] = 1.87-3.10, P < 0.001) and cardiovascular mortality (HR = 3.39, 95% CI = 2.17-5.31, P < 0.001) compared to those in the lowest quartile. Each unit increase in RAR was associated with a 93% increase in all-cause mortality (HR = 1.93, 95% CI = 1.62-2.30, P < 0.001) and a 130% increase in cardiovascular mortality (HR = 2.30, 95% CI = 1.83-2.90, P < 0.001). No significant nonlinear associations were found. A significant age interaction was observed in all-cause mortality (P for interaction < 0.05), with stronger associations seen among younger individuals. Sensitivity analyses confirmed the robustness of these findings.
conclusionsHigher RAR levels were significantly associated with increased all-cause and cardiovascular mortality in adults with MASLD. RAR holds potential as a risk stratification tool for MASLD adults in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.